Overall Survival (OS) is the only endpoint solely based on survival events, fairly objective, and precisely measurable.

Boehringer Ingelheim revealed that their interchangeable* biosimilar to Humira®, known as Adalimumab-adbm injection, is now available at a low wholesale acquisition cost.

This article summarized the latest R&D progress of diclofenac diethylamine, the Mechanism of Action for diclofenac diethylamine, and the drug target R&D trends for diclofenac diethylamine.

Caliway Biopharmaceuticals announced successful primary and secondary endpoints of the phase 2 stage 2 trial for CBL-0202, outperforming placebo in ITT and PP groups.

EMBL-EBI offers a plethora of widely trusted online tools for sequence alignment. Moreover, our emphasis is laid on a profound recommendation: a user-friendly, commercial Patsnap Bio Sequence Database sequence alignment tool, which commendably offers free registration.

The U.S. FDA has granted Priority Review to Rocket Pharmaceuticals, Inc. for their late-stage gene therapy, RP-L201 (marnetegragene autotemcel).

This article summarized the latest R&D progress of cabotegravir/rilpivirine, the Mechanism of Action for cabotegravir/rilpivirine, and the drug target R&D trends for cabotegravir/rilpivirine.

Presenting new preclinical data on LASN01 for treating TED, Lassen Therapeutics, a biotechnology firm engaged in clinical stages, is pioneering unique antibody therapeutics.

The role of the MR (Mineralocorticoid Receptor) in the human body is crucial for maintaining electrolyte and fluid balance.

Kashiv BioSciences, LLC declared the start of enrollment for their Phase III clinical trial initiating with their first patient for their biosimilar candidate, ADL018, a potential alternative to XOLAIR®.

This article summarized the latest R&D progress of bupivacaine hydrochloride, the Mechanism of Action for bupivacaine hydrochloride, and the drug target R&D trends for bupivacaine hydrochloride.

Nexcella Inc. revealed updates from its ongoing Phase 1b/2 NEXICART-1 trial on its proprietary BCMA-targeted CAR T cell treatment, NXC-201.